Phathom Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Phathom Pharmaceuticals

07/08/2025 17:50

Phathom Pharmaceuticals Inc PHAT.OQ reported a quarterly adjusted loss of $1.05​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.56.  The mean expectation of eight analysts for the quarter was for a loss of $1.04 per share. Wall Street expected results to range from $-1.27 to -88 cents per share.

Revenue rose 439.4% to $39.50 million from a year ago; analysts expected $36.08 million.

Phathom Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.05​.

The company reported a quarterly loss of $75.81 million.

Phathom Pharmaceuticals Inc shares had fallen by 9.5% this quarter and gained 6.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 6.7% in the last three months.​

In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $18.50, about 53.1% above its last closing price of $8.68

This summary was machine generated from LSEG data August 7 at 04:49 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.04
-1.05
Missed
Mar. 31 2025
-1.15
-1.31
Missed
Dec. 31 2024
-1.27
-1.05
Beat
Sep. 30 2024
-1.49
-1.32
Beat